Bevacizumab biosimilar LY01008 demonstrated comparative safety, efficacy, immunogenicity, and pharmacokinetic profiles to the reference product Avastin when combined with paclitaxel and carboplatin in ...

SEATTLE -- Availability of a bevacizumab (Avastin) biosimilar for ophthalmic use could have the unintended consequence of driving up the cost of treating retinal disease with angiogenesis inhibitors, ...

Bevacizumab (Avastin, Genentech/Roche) is already approved for use in combination with chemotherapy as a first-line treatment for metastatic colorectal cancer, but the drug now has an extended ...

On July 29, 2021, the American Academy of Ophthalmology (AAO) released a statement urging the Centers for Medicare & Medicaid Services (CMS) to prohibit Insurance companies from requiring ...

– Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of ...

Please provide your email address to receive an email when new articles are posted on . Researchers observed reduced risk for disease progression and death with the investigative combination.

According to Liu, his preferred option is faricimab, a fairly new agent that was FDA-approved for wet AMD in 2022. The drug ...

Bevacizumab (Avastin, Roche/Genentech) significantly extended survival by nearly 4 months in patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard surgery ...

Nicholas G. Anderson, MD, leads a discussion on how the first ophthalmic formulation of bevacizumab may impact the wet AMD treatment paradigm. Jim Kenney, RPh, MBA: We don’t always get extrapolation ...

Please provide your email address to receive an email when new articles are posted on . Mirvetuximab soravtansine in combination with bevacizumab demonstrated antitumor activity with durable responses ...